PSI Opens New Italian Office

PSI Opens New Italian Office

ZUG, Switzerland--(BUSINESS WIRE)--Today, PSI CRO, a full-service contract research organization, announced opening of a new operational office in Italy. The Italian office further expands PSI's well-established presence in Europe and strengthens PSI's ability to deliver global clinical trials. The PSI CRO Italy S.r.l. office is located just outside Milan at Via Badia n.55, 20060 Gessate. It will give PSI the location and support to continue attracting and recruiting top talent in the industry.

PSI has been placing clinical trials in Italy for a number of years on behalf of pharmaceutical and biotech sponsors. They have gained extensive knowledge and experience with local investigative sites in the areas of oncology, haematology, haemophilia, acute care, infectious diseases, CNS, diabetes, and other therapeutic areas.

About PSI CRO AG: PSI is a privately held, full-service contract research organization (CRO), operating globally. PSI positions itself as a no-nonsense CRO capable of saving pharmaceutical sponsors millions of development dollars by consistently meeting clinical trial timelines. PSI's global reach supports the operations of clinical trials across multiple countries and continents. PSI has exceptionally high repeat and referral business rates that are indicative of a commitment to be the best CRO in the world as measured by clients and employees. Global headquarters are located in Zug, Switzerland at 113a Baarerstrasse 6300. www.psi-cro.com

Contacts

PSI Inquiries to:
PSI CRO AG
Corporate Headquarters
Myrna Sanchez, +41 41 228 10 00
[email protected]
or
Media Inquiries:
Ripple Effect Communications
Valerie Harding, +1 617-536-8887
[email protected]

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.